Your Health, We Care
Bosentan is metabolized by CYP2C9 and CYP3A. Inhibition of these enzymes may increase the plasma concentration of bosentan. Concomitant use of CYP2C9 inhibitors with strong or moderate CYP3A inhibitors is not recommended.
Bosentan is an inducer of CYP3A and CYP2C9. Concomitant use with TRACLEER reduces the plasma concentrations of drugs metabolized by these two isozymes.
Hormonal contraceptives (including oral, injectable, transdermal, and implantable forms) may be unreliable when used concomitantly with bosentan. Women should use additional contraceptive methods and should not rely solely on hormonal contraception.
FDA，2025.07
